BCR/ABL Fusion Probe
Product Description:chronic myeloid leukemia(CML)
Applications: Lymphatic hematopoietic system tumor
BCR/ABL gene fusion probe
1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.
2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.
3.Reproducibility: Different laboratories test results are highly reproducible.
The ABL probe was labeled with orange red dye and the green dye was used to mark the BCR probe. In situ hybridization technique could be used to combine the two probes into the target detection site.
BCR/ABL fusion gene is a common cytogenetic anomaly in patients with chronic myelocytic leukemia (CML). The BCR/ABL fusion gene can be found in 90% of the CML patients. The prognosis of patients with BCR/ABL fusion gene is poor. It is clinically possible to use the BCR/ABL fusion gene to selectively use the molecular targeted therapeutic drugs . In addition, clinicians can combine other signs of patients to identify patients more effectively.